Symbotic stock price staged a strong comeback on Monday after the warehouse technology company published strong financial results. SYM shares jumped by over 26%, reaching a high of $38.60, its highest level since July this year. It has soared by 124% from its lowest level this year, bringing its valuation to almost $20 billion.

Symbotic stock soars after earnings

Symbotic is a leading company that provides warehouse technology to companies like Walmart, Target, Albertsons, Giant Tiger, and C&S Wholesale. Walmart is a big shareholder in the company. 

Symbotic solutions automate warehouses, reduce the number of workers in them, save money, and boost efficiency. Their platform is powered by eight key technologies, such as artificial intelligence, randomizing, autonomous movements, and atomizing.

Symbotic and other similar warehousing companies have done well in the past few years as demand for e-commerce rose. Today, while companies like Target and Walmart do a lot of their business in stores, they have become big names in the e-commerce industry. For example, Walmart’s e-commerce revenue jumped to over $82 billion in 2023.

Symbotic stock price jumped after the company published encouraging financials on Monday. Its fourth-quarter revenue rose to $576 million, up from $391 million in the same period in 2023. 

Its full-year revenue jumped to $1.8 billion from the $1.17 billion it made in the last financial year. Most of this revenue came from its systems business followed by operation services and software maintenance. 

Symbotic also turned a profit in the last quarter. Its net income jumped to over $28 million, a big improvement from the $45 million loss it made a year earlier. Its annual loss improved to $50.6 million from $207 million a year earlier. 

Symbotic believes that its business will continue doing well because of its strong backlog. Analysts expect that its revenue will rise by 34% in the current quarter to $493.6 million.

The average revenue estimate for the new financial year is $2.34 billion, a 28% increase from what it reported on Monday. This revenue will explode to $3.2 billion in the next financial year, helped by strong demand.

Symbotic’s results will likely be better than estimates since the company has a long track record of outperforming expectations. 

Read more: Symbotic stock is heavily shorted: is it a good contrarian buy?

Analysts are upbeat on the SYM stock

Wall Street analysts are upbeat about the SYM stock price. The average stock estimate is $39.38, much higher than the current $30. 

Some of the most optimistic analysts are from Cantor Fitzgerald, Baird, and Deutsche Bank, who see the stock rising. 

However, the biggest concern among some analysts is Symbotic’s valuation, which is quite substantial. The company trades at a forward price-to-sales ratio of over 7, which is significantly higher than most companies.

The other key concern is whether there is more room for growth since most retailers have put in place their warehouses. Also, the company operates in a low-margin business. It hasa gross margins of 17.25%, much lower than the industrial margin of 32.

Symbotic share price analysis

SYM chart by TradingView

The daily chart shows that the SYM share price has made a strong rebound after publishing its financial results. This rebound happened after the stock formed an ascending channel shown in black. It retested the lower side of the channel on Monday.

Symbotic shares have moved above the upper side of the ascending channel and moved above the 50% Fibonacci Retracement level. Also, the Relative Strength Index (RSI) and the MACD indicators have pointed upwards.

Therefore, the stock will likely continue rising as bulls target the key resistance at $50, its highest swing on March 26, which is 63% above Monday’s close. The stop-loss of this trade is at $30. 

The post Symbotic stock analysis: is it too late to buy the soaring SYM? appeared first on Invezz

Algorand price continued its recovery, surging to a high of $0.2318, its highest level since April 24 as cryptocurrencies bounced back. ALGO has jumped by over 124% from its lowest level this year, bringing its market cap to over $1.7 billion. 

Algorand price nears a golden cross

The odds of more ALGO upside are rising as the token nears a golden cross pattern, which happens when the 200-day and 50-day Exponential Moving Averages (EMA) cross each other. 

The spread between the two averages has narrowed to just $0.0042, meaning that it could happen if ALGO rises slightly.

In most cases, this pattern usually leads to more gains over time. For example, Algorand price formed a golden cross in January, resulting in a 100% jump to the year-to-date high of $0.3291. 

ALGO has more positive technicals. It has moved above the Ichimoku cloud indicator, while the Relative Strength Index (RSI) and the Stochastic Oscillator have all pointed upwards. The RSI has moved to 73, while the Stochastic moved to the overbought level.

Algorand price has moved above the descending trendline, which is an inverse head and shoulders pattern. In technical analysis, this is one of the top bullish signs in the market. The MVRV indicator has also risen to 2.9, pointing to potential gains in the near term.

Algorand has also moved to the 50% Fibonacci Retracement level at $0.2100. Therefore, the outlook for the ALGO token will likely continue rising as bulls target the year-to-date high of $0.3290, which is about 56% above the current level. 

It is highly unlikely for Algorand to jump to $1, which would imply a 400% jump from the current level.

On the flip side, a drop below the key support at $0.1818, the 38.2% retracement level will invalidate the bullish view. If this happens, the next point to watch will be at $0.1500.

Read more: Algorand (ALGO) price targets 60% breakout amid demand resurgence

Analysts are bullish on ALGO token

Crypto analysts are bullish on the Algorand price. In an X post this week, MrBags, a crypto analyst noted that the coin was showing strength, pointing to the upcoming staking rewards. Also, Algorand has a low inflation rate of 2.7% until 2030, lower than other popular coins.

Some of the potential catalysts for the Algorand price are FiFA Connect, which has handled over 1.3 million transactions, Lofty AI, which has paid $3 million in rental income, and Travelex.

Other analysts note that Algorand price may seek to soar to $1 as investors rotate from the expensive Solana and Ethereum. Solana has recently jumped to $250, making it more expensive to most investors.

Challenges remain

Still, the biggest challenge for Algorand price is its ecosystem, which has remained under pressure over time. Data shows that Algorand, one of the oldest layer-2 networks has only $106 million in total value locked (TVL). This is a tiny figure compared to other newer blockchains. 

In contrast, Solana has over $8 billion in assets, while Base, which was launched last year, has 43.2 billion and 1.3 million users. Sui has also accumulated $1.6 billion. 

Algorand also has little going on in its DEX ecosystem. Solana handled $42 billion in volume in the last seven days while Ethereum, Base, and Arbitrum handled $14 billion, $11.5 billion, and $9.32 billion, respectively. 

Algorand, on the other hand, handled just $38 million in that period, making it the 32nd biggest player in the industry. This makes it smaller than many networks like Scroll, Injective, Stellar, and Gnosis. 

Algorand’s low volume is mostly because the network has no presence in the meme coin industry, which has helped to propel Solana into the biggest chain for DEX transactions in the crypto sector.

The post Algorand price prediction: rare pattern points to more ALGO gains appeared first on Invezz

Affirm stock price rose for four consecutive weeks as investors cheered the ongoing Federal Reserve interest rate cuts and its partnerships with top companies. AFRM jumped to a high of $62 on Monday, its highest level since February 2022. It has soared by over 570% from its lowest point in 2023.

Affirm has inked numerous partnerships

The main catalyst for the Affirm stock surge this week was its decision to expand its partnership with Priceline, one of the top players in online travel. This partnership will focus on Priceline’s business-to-business solutions, which include companies like airlines, cruise lines, hotels, and car rentals. 

Affirm has also inked numerous deals in the past few years. The most notable one was its partnership with Amazon, the biggest e-commerce company globally. That deal allows customers to select Affirm as a checkout option. Most recently, Affirm partnered with Apple Pay, giving it access to millions of customers.

It has also partnered with Hotels.com, a company owned by Expedia Group, as it seeks to expand its business in the leisure market. The company also partnered with Tekmetric, RONA, Brittain Resorts & Hotels, and Alterra Mountain. Altogether, the number of merchants using Affirm has grown to 323,000, a number that will likely continue growing. 

These partnerships have helped to transform Affirm into one of the fastest-growing companies in the industry. Its annual revenue has soared from $509 million in 2020 to over $2.3 billion last year. Also, the number of Affirm’s active customers rose to over 19.5 million. 

Analysts expect that Affirm’s business will continue doing well this year, with its revenue expected to hit $3.17 billion followed by $3.7 billion in the next financial year.

Read more: Here’s why Affirm stock could surge another 50%

AFRM had a strong quarter

Affirm stock price rallied after the company published strong financial results, signaling that its business was doing well.

Its gross merchandise volume jumped by 35% to over $7.6 billion in the first quarter of 2025. This growth led to a 41% increase in its revenue, which jumped to $698 million. Its revenue less transaction costs was $285 million. 

The management believes that the industry is yet to scratch the surface since it has had a penetration rate of less than 8%. 

It, therefore, expects that its business will continue doing well. Its next quarter’s GMV is expected to be between $9.35 billion and $9.75 billion. Its revenue for the quarter will be between $770 million and $810 million, with its operating margin being between 21% and 23%.

Affirm’s growth has been because of its business model, which many customers believe is better than credit cards. Unlike credit cards, Affirm does not charge interest for most of its offerings. It allows customers to buy for products and pay for them in equal installments. 

Customers can select to pay for a longer period and pay interest. In some instances, the interest charged is usually less than that of credit cards. As such, Affirm has a large TAM since over 80% of all US adults have at least one credit card. 

Affirm’s key challenge is that its business is that its business is facing substantial competition from top companies like Klarna and AfterPay. The other challenge is that the current stock price of $62 is lower than the average Wall Street estimate of $49.

Still, looking ahead a decade from now, I suspect that Affirm will be a significantly bigger company than it is today. 

Affirm stock price analysis

AFRM chart by TradingView

The weekly chart shows that the AFRM share price has been in a strong comeback in the past few months. It has risen in the past four weeks, reaching its highest level since 2022. 

Affirm has moved above the key resistance level at $52.65, its highest level in December last year. By moving above that resistance, it invalidated the double top chart pattern.

Affirm stock price moved above the overbought point. Similarly, the MACD indicator has moved above the zero line. 

Therefore, the path of the least resistance for the AFRM stock is $100, which is about 625 above the current level. A drop below the support at $52.6 will invalidate the bullish sign.

The post Affirm stock price is soaring: will AFRM surge to $100 soon? appeared first on Invezz

The SPDR S&P Regional Banking (KRE) ETF stock price continued its strong rally, reaching its highest level at $67.95, its highest swing since February 2022. It has soared by 100% from its lowest level last year when the regional banking crisis escalated.

Regional banks have bounced back

The KRE ETF is a leading fund with 143 companies and over $4.9 billion in assets under management. 

It is a top fund that holds companies like M+T Bank, Huntington Bancshares, Regions Financial, Truist, First Horizon, and Zions Bancorp. 

The fund came into the spotlight last year after a series of regional bank collapses like companies like Silicon Valley Bank (SVB), Signature Bank, and First Republic. These were some of the most notable bank collapses in the last decade.

Their collapses led to a substantial risk that other regional banks would also go bankrupt. A major risk was that most of these banks have substantial exposure in Commercial Real Estate (CRE), which has over $950 billion in maturities this year. 

Regional banks are more exposed to the CRE industry because many large companies like JPMorgan and Goldman Sachs have reduced their exposure. The distress in the real estate industry has not happened.

Additionally, there were concerns about their investments in government bonds, whose values dropped when interest rate surged. 

Read more: FDIC proposes new rules for regional banks to better prepare for a potential collapse

M&T Bank and other constituents have soared

A closer look at most companies in the KRE ETF have done well in the past few months. M&T Bank stock price has jumped to $215, up by over 106% from its lowest level in October last year as it continued to publish strong results. 

The most recent numbers showed that M&T Bank’s net income interest rose to $1.72 billion, up from $1.718 billion in the second quarter. 

Huntington Bancshares stock has soared in the past three consecutive weeks, reaching a high of $18. It has risen by 110% from its lowest point in 2023. Similarly, Regions Financial shares have jumped to $26.3, also higher than last year’s low of $13.1

Other top-performing companies in the ETF like Truist Financial, First Horizons, Zions Bancorp, and Bank OZK. 

Analysts believe that the KRE ETF is a fairly undervalued fund trading at a forward P/E ratio of 14, lower than the S&P 500 of 21. The price-to-cash flow multiple of 11.85 is also lower than the fund. 

These valuation metrics are mostly because of the lingering fear that regional banks may collapse again as the Federal Reserve cuts rates.

KRE ETF analysis

KRE chart by TradingView

The weekly chart shows that the SPDR S&P Regional Banking ETF has been in a strong bull run in the past few months.

KRE has formed an ascending channel shown in black. It has moved to the upper side of this channel.

The stock has moved above the key resistance level at $60, its highest level in July this year. It has also rallied above the key point at $64.15, its highest swing in August 2022.

KRE has formed a golden cross as the 50-day and 200-day Exponential Moving Averages (EMA) have formed a golden cross pattern. In most cases, this pattern usually leads to substantial gains. 

The MACD and the Relative Strength Index (RSI) have continued rising, which is a sign of strong momentum. It has also risen above the 23.6% retracement point.

The KRE ETF has formed a doji candlestick pattern. Therefore, while the stock has more upside going forward, there is a likelihood that it will pullback in the coming days and retest the support at $59.22.

The post KRE ETF stock has doubled: is it safe to buy regional banks? appeared first on Invezz

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October last year. It has dropped by 27% from the year-to-date high.

Good news from GSK

The GSK share price rose slightly after the company announced positive result for its linerixibat, a drug that will be used to treat relentless itching caused by primary biliary cholangitis (PBC).

This is a notable development since PBC is a common rare disease that can lead to liver failure among patients. GSK is now in the third phase of this trial, which is known as GLISTEN. In this trial, the company said that the drug helped to reduce itching over a 24 weeks compared to a placebo.

GSK is also carrying more trials in its pipeline. Some of the drugs in the third phase are gepotidacin, which will be used to treat urogenital gonorrhoea, bepirovirsen (Chronic hepatitis B virus infection), linerixibat (Cholestatic pruritus in primary biliary cholangitis), and mepolizumab nucala for chronic obstructive pulmonary disease.

GSK earnings and RFK jr

The GSK share price has slumped after Donald Trump nominated Robert Kennedy Jr to be the next head of the DHS. This is a notable appointment because Kennedy, who has no medical training, has spent decades raging against the pharmaceutical industry.

Kennedy believes that many of these companies, including GSK, have misled the public and worked in conjunction with health officials to promote vaccines. He has become one of the top promoters of the theory that vaccines are not good.

Still, it is unclear whether Kennedy will get the required votes to become the head of the department. Besides, pharmaceutical companies, including GSK have contributed money to legislators. Data shows that the company donated $564,138 in the last political season. It sent $30,885 to the National Republican Senatorial Committee. 

Meanwhile, GSK reported relatively weak financial results. Its total revenue dropped by 2% to £8 billion during the quarter.

This decline happened as vaccine sales plunged by 15% because of the waning demand for COVID-19 vaccines. This drop was offset by specialty drugs sales whose revenues rose by 19%, oncology (94%), and HIV (12%). General medicines revenue rose by 7%. 

Some of this growth was mostly because of its acquisitions. It acquired Aiolos Bio earlier this year in a $1 billion deal. It will also need to pay $400 million per future milestones. 

GSK also bought Sierra Oncology for $1.9 billion, a deal that gave it access to momelotinib, a drug that treats anemia. GSK’s operating profit dipped by 86% as its cash from operations jumped to £2.5 billion. 

Read more: GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside

GSK share price analysis

The weekly chart shows that the GSK stock price has been in a strong bearish trend in the past few months. It has fallen from the year-to-date high of 1,782p to 1,300p as concerns about its slow growth continued. 

GSK has dropped below the 50-week and 200-week Exponential Moving Averages (EMA), meaning that bears are now in control. It is also attempting to drop below the psychological level at 1,300p.

GSK has also dropped below the 38.2% Fibonacci Retracement level. The Relative Strength Index (RSI) and the Stochastic Oscillator have all pointed downwards. 

Therefore, the GSK share price will likely continue falling as sellers target the 50% retracement level at 1,250p, which is about 5% below the current level. A drop below that level will point to more sell-off to the 61.8% retracement point at 1,123p. On the flip side, a move above the psychological level at 1,375p will invalidate the bearish view.

The post GSK share price is imploding: is it safe to buy the dip? appeared first on Invezz